It’s not Novartis’s first attempt to defend Entresto. Last December, the company filed a lawsuit against Torrent Pharma, alleging patent infringement when Torrent submitted its generic application. The company argued that if Torrent were to move forward with production, it would be doing so knowing its actions constitute patent infringement, which would be “substantially and irreparably” damaging to Novartis.

Meanwhile, last month, the company petitioned the FDA to not approve generics of the drug until the end of its three-year exclusivity period that lasts until February 2024. That move followed a similar but unsuccessful appeal last November.

Last year, Entresto garnered nearly $3.55 billion in global sales. The company has maintained that the drug could deliver peak sales of $5 billion.